

COVID-19 vaccine and booster dose schedules and guidance

Table A. COVID-19 vaccination schedules for **primary and booster doses**

Table B. COVID-19 schedules for **people with moderate or severe immunocompromising conditions**

Table C. Guidance for anyone 12 years or older who received **non-FDA-approved vaccine**

Table A. COVID-19 vaccination primary series and booster dose schedule							
Primary series vaccine manufacturer	Age group	Number of doses in primary series	Number of booster doses	Interval between 1 st and 2 nd doses	Interval between 2 nd and 3 rd doses	Interval between primary series and booster dose	Interval between 1 st boost and 2 nd boost dose
Pfizer	6m - 4 years	3	N/A	≥ 3 - 8 weeks	≥ 8 weeks	N/A	N/A
Pfizer	5 - 11 years	2	1	≥ 3 - 8 weeks*	N/A	≥ 5 months	N/A
Pfizer	12 - 49 years	2	1	≥ 3 - 8 weeks*	N/A	≥ 5 months	N/A
Pfizer	50 + years	2	2	≥ 3 - 8 weeks*	N/A	≥ 5 months	≥ 4 months
Moderna	6m - 5 years	2	N/A	≥ 4 - 8 weeks*	N/A	N/A	N/A
Moderna	6 - 11 years	2	N/A	≥ 4 - 8 weeks*	N/A	N/A	N/A
Moderna	12 - 17 years	2	N/A	≥ 4 - 8 weeks*	N/A	N/A	N/A
Moderna	18 - 49 years	2	1	≥ 4 - 8 weeks*	N/A	≥ 5 months	N/A
Moderna	50 + years	2	2	≥ 4 - 8 weeks*	N/A	≥ 5 months	≥ 4 months
Janssen	18 - 49 years	1	1 - 2**	N/A	N/A	≥ 8 weeks	**≥ 4 months IF Janssen was given for 1 st booster
Janssen	50 + years	1	2	N/A	N/A	≥ 8 weeks	≥ 4 months

*An **8-week** interval may be optimal for people ages 5 years through 64 years, especially for males 12 through 39 years, who are not moderately or severely immunocompromised. The **shorter intervals** of 3 weeks for Pfizer and 4 weeks for Moderna remains the recommended interval for people who are moderately or severely immunocompromised***, adults ages 65 years and older, and those determined to need early protection by their health care professional.

Table B. COVID-19 vaccination schedule for people with moderate or severe immunocompromise***

Primary series vaccine manufacturer	Age group	Number of doses in primary series	Number of booster doses	Interval between 1 st and 2 nd dose	Interval between 2 nd and 3 rd dose	Interval between primary series and 1 st booster	Interval between 1 st and 2 nd boost doses
Pfizer	6m - 4 years	3	N/A	≥ 3 weeks	≥ 8 weeks	N/A	N/A
Pfizer	5 - 11 years	3	1	≥ 3 weeks	≥ 4 weeks	≥ 3 months	N/A
Pfizer	12- 49 years	3	2	≥ 3 weeks	≥ 4 weeks	≥ 3 months	≥ 4 months
Pfizer	50 + years	3	2	≥ 3 weeks	≥ 4 weeks	≥ 3 months	≥ 4 months
Moderna	6m - 5 years	3	N/A	≥ 4 weeks	≥ 4 weeks	N/A	N/A
Moderna	6 - 11 years	3	N/A	≥ 4 weeks	≥ 4 weeks	N/A	N/A
Moderna	12 - 17 years	3	2	≥4 weeks	≥ 4 weeks	≥ 3 months	≥ 4 months
Moderna	18 - 49 years	3	2	≥4 weeks	≥ 4 weeks	≥ 3 months	≥ 4 months
Moderna	50 + years	3	2	≥4 weeks	≥ 4 weeks	≥ 3 months	≥ 4 months
Janssen	18 - 49 years	1 + 1 mRNA	2 mRNA	≥4 weeks	N/A	≥ 8 weeks	≥ 4 months
Janssen	50 + years	1 + 1 mRNA	2 mRNA	≥4 weeks	N/A	≥ 8 weeks	≥ 4 months

***Moderate and severe immunocompromising conditions and treatments include but are not limited to:

- Undergoing active cancer treatments
- Solid-organ transplant recipient and taking immunosuppressive therapy
- Chimeric antigen receptor T-cell recipient or hematopoietic cell transplant (within 2 years)
- Moderate or severe primary immunodeficiency
- Advanced or untreated HIV infection
- Active treatment with high-dose corticosteroids

Table C. COVID-19 vaccination guidance for people ≥ 12 years who received non-FDA-approved vaccine

Probable scenarios	<i>Moderately or severely immunocompromised***</i>	Was vaccine received listed for emergency use by WHO?	Non-FDA-approved vaccine doses received	Recommended FDA-approved vaccine primary series	Interval in between	Recommended FDA-approved vaccine booster	Interval in between
Scenario 1 ¹	No	Yes	All recommended	N/A	--	mRNA	≥ 5 mo.
Scenario 1 ¹	Yes	Yes	All recommended	mRNA-single	≥ 28 days	mRNA	≥ 3 mo.
Scenario 2 ²	No	Yes	Partial	mRNA-single	≥ 28 days	mRNA	≥ 5 mo.
Scenario 2 ²	Yes	Yes	Partial	mRNA-single	≥ 28 days	mRNA	≥ 3 mo.
Scenario 3 ³	No	No	All or some of recommended	Any-full series	≥ 28 days	mRNA	≥ 5 mo.
Scenario 3 ³	Yes	No	All or some of recommended	Any-full series	follow Table B guidance for this group		

^{1 2 3}Guidance for people who received non-FDA-approved vaccine:

Scenario 1: 12 years or older and has completed all of the recommended primary doses of a COVID-19 vaccine listed for emergency use by WHO:

- Should get an mRNA boost dose **5 months after** completing the last primary dose of the non-FDA-approved vaccine, unless they received a booster after completion of the primary series; the booster dose will not be repeated.
- Moderately to severely immunocompromised*** are eligible for a single dose of an mRNA **28 days after** their last dose of the non-FDA-approved primary series.

Scenario 2: 12 years or older and has only received a partial primary series of a COVID-19 vaccine listed for emergency use by WHO:

- Should get an mRNA single **dose at least 28 days after** the 1st dose to be considered fully vaccinated.
- Should get an mRNA boost dose **5 months after** completing their primary series.
- Moderately to severely immunocompromised** after completion of their primary series with Pfizer are eligible for a 3rd dose of Pfizer **28 days after** 2nd dose.

Scenario 3: 12 years or older and received all of some doses of a COVID-19 vaccine not listed for emergency use by WHO:

- Should be offered a COVID-19 FDA-approved primary series **28 days** after their last dose.
- Should get an mRNA boost dose **5 months after** completing their primary series.
- Moderately to severely immunocompromised*** should restart a primary series. Use the number and timing guidance in Table B for this group.

For further and more detailed information, refer to the [CDC's ICCs](#). For questions or concerns reach out to UDOH Immunization Program at 801-538-9450 or covidvaxprovider@utah.gov